Inclusion completed

An open-label, non-randomised, multicentre phase 1/2 trial of RO5424802 given orally to non-small cell lung cancer patients who have ALK mutation and failed crizotinib treatment.

Cancer type: Head and Neck cancer

Phase: I/II

Principal Investigator: Tell Roger

Country: SE

Keywords: Sweden, 2012-004455-36, JEB

Status: Inclusion completed